Compare FAT & ABP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FAT | ABP |
|---|---|---|
| Founded | 2017 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 25.4M | 18.8M |
| IPO Year | 2017 | N/A |
| Metric | FAT | ABP |
|---|---|---|
| Price | $0.52 | $5.88 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 1 |
| Target Price | ★ $10.00 | N/A |
| AVG Volume (30 Days) | ★ 478.7K | 32.0K |
| Earning Date | 11-05-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $574,143,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $7.74 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 50.00 |
| 52 Week Low | $0.36 | $4.55 |
| 52 Week High | $6.17 | $153.90 |
| Indicator | FAT | ABP |
|---|---|---|
| Relative Strength Index (RSI) | 20.44 | 63.00 |
| Support Level | $0.49 | $5.18 |
| Resistance Level | $0.65 | $7.02 |
| Average True Range (ATR) | 0.15 | 0.55 |
| MACD | -0.02 | -0.27 |
| Stochastic Oscillator | 13.82 | 34.87 |
FAT Brands Inc is a multi-brand restaurant franchising company. It develops, markets, acquires, and manages quick service, fast casual, casual dining, and polished casual dining restaurant concepts around the world. The company operates as a franchisor of restaurants, where the company generally does not own or operate the restaurant locations but rather generates revenue by charging franchisees an initial franchise fee as well as ongoing royalties. For some of the company's brands, it also directly owns and operates restaurant locations. Its brands include Round Table Pizza, Fatburger, Johnny Rockets, Twin Peaks, and Elevation Burger among others. Geographically, the majority of the revenue for the company is generated from the United States.
Abpro Holdings Inc is a biotechnology company dedicated to developing next-generation antibody therapeutics with the goal of improving the lives of patients with severe and life-threatening diseases. It is focused on novel antibody constructs for immuno-oncology and ophthalmology. By leveraging its proprietary DiversImmune and MultiMabTM antibody discovery and engineering platforms. The company is developing a pipeline of next-generation antibodies, both independently and through collaborations with pharmaceutical and research institutions.